Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)
Regulatory Filings Classification · 82% confidence The document is a disclosure titled “투자판단 관련 주요경영사항(임상시험 계획 승인 등 결정)” announcing that the company received approval for a Phase 1 clinical trial plan from the European EMA. It contains descriptive details of the trial, dates, protocol, and risk notes. There are no financial statements, results, proxies, board changes, capital actions, or dividend information. This is a material event announcement filed with the regulator and does not fit into specialized categories like earnings release, annual or interim report, proxy materials, or ESG report. Therefore it falls into the general Regulatory Filings category (RNS).
2026-05-29 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is a detailed quarterly report (“분기보고서”) covering the period January 1, 2026 to March 31, 2026. It contains comprehensive financial statements, business overview, segment data, subsidiaries, capital changes, share info, and product sales breakdown. This matches the definition of an Interim / Quarterly Report, not merely an announcement or summary. Q1 2026
2026-05-15 Korean
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 89% confidence The document is a convocation notice (“주주총회소집결의”) for an extraordinary shareholders’ meeting, detailing the meeting date, record date, agenda (election of an outside director), and candidate information. This type of shareholder meeting notice and agenda material aligns with Proxy Solicitation & Information Statement filings, which provide information to shareholders and request their votes. It is not the AGM presentation, not the actual voting results, nor a dividend notice, and it is more than just a brief RPA. Therefore, it is classified as a PSI.
2026-04-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a notification to the Financial Services Commission/Korea Exchange reporting the appointment, dismissal, or mid-term resignation of an outside director (“사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고”). This matches the definition of Board/Management Information (MANG) for announcements of changes in the board of directors.
2026-04-27 Korean
주주명부폐쇄기간또는기준일설정
Declaration of Voting Results & Voting Rights Announcements Classification · 75% confidence The document is an official announcement setting the record date (기준일) and book‐closure period for the shareholders’ register in order to determine voting rights for an upcoming extraordinary general meeting. It is not the results of a vote, but it is clearly a voting rights announcement (e.g., notice of record date/book closure for shareholders). Therefore, it best fits the Declaration of Voting Results & Voting Rights Announcements category (Code: DVA).
2026-04-27 Korean
불성실공시법인지정 (공시불이행)
Regulatory Filings Classification · 90% confidence The document is an official regulatory announcement in Korean regarding the designation of 삼천당제약 as a non-compliant disclosure company (불성실공시법인 지정) under KOSDAQ regulations, detailing dates, penalty points, and regulatory references. It is not a financial report, earnings release, management change, or share transaction. This falls under miscellaneous regulatory filings.
2026-04-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.